Question 1

What is the difference between SKYRIZI and Stelara?

Accepted Answer

SKYRIZI is SKYRIZI (risankizumab) is a monoclonal antibody that selectively blocks the IL-23 cytokine pathway by binding to the p19 subunit of IL-23. and is developed by Chong Kun Dang Pharmaceutical. Stelara is Stelara binds to the p40 subunit of IL-12 and IL-23, reducing inflammation in autoimmune diseases. and is developed by Biocon Biologics UK Ltd.

Question 2

What are SKYRIZI and Stelara used for?

Accepted Answer

SKYRIZI: Moderate to severe plaque psoriasis, Crohn's disease, Ulcerative colitis. Stelara: Crohn's disease, Plaque psoriasis, Psoriasis.

Question 3

Are SKYRIZI and Stelara in the same drug class?

Accepted Answer

No — SKYRIZI is IL-23 inhibitor monoclonal antibody and Stelara is an uncategorised drug.

	SKYRIZI	Stelara
Generic name	SKYRIZI	Stelara
Sponsor	Chong Kun Dang Pharmaceutical	Biocon Biologics UK Ltd
Drug class	IL-23 inhibitor monoclonal antibody	—
Molecular target	IL-23 (p19 subunit)	Interleukin-12, Interleukin-23
Modality	Biologic	Biologic
Phase	FDA-approved	FDA-approved
Therapeutic area	Immunology/Dermatology	Immunology

SKYRIZI vs Stelara

At a glance

Mechanism of action

Approved indications

SKYRIZI

Stelara

Common side effects

SKYRIZI

Stelara

Further reading

SKYRIZI	SKYRIZI (risankizumab) is a monoclonal antibody that selectively blocks the IL-23 cytokine pathway by binding to the p19 subunit of IL-23.
Stelara	Stelara binds to the p40 subunit of IL-12 and IL-23, reducing inflammation in autoimmune diseases.